- MLL rearrangements are found in 5% to 10% of adult AML and B-ALL cases and >70% of infant leukemias
- NPM1 mutations are found in about 25% to 30% of all adult AML
A Phase 1/2 trial investigating orally administered revumenib in patients with MLLr or mNPM1 acute leukemias1,2
Revumenib capsules orally and pre-specified chemotherapy regimens1,3
If you are interested in learning more about enrolling your adult and pediatric relapsed/refractory patients in AUGMENT-101, contact us directly at email@example.com.
- A study of SNDX-5613 in R/R leukemias including those with an MLLr/KMT2A gene rearrangement or NPM1 mutation (AUGMENT-101). ClinicalTrials.gov identifier: NCT04065399. https://clinicaltrials.gov/ct2/show/NCT04065399. Updated September 16, 2019. Accessed November 12, 2019.
- Data on file. Syndax Pharmaceuticals, Inc.
- Kuhn MW, Armstrong SA. Designed to kill: novel menin-MLL inhibitors target MLL-rearranged leukemia. Cancer Cell. 2015;27(4):431-433.
- Kuhn MW, Song E, Feng Z, et al. Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia. Cancer Discov. 2016;6(10):1166–1181.
- Ley TJ, Miller C, Ding L, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368(22):2059–2074.